Login / Signup

VERVE-101, a CRISPR base-editing therapy designed to permanently inactivate hepatic PCSK9 and reduce LDL-cholesterol.

Amanda J HooperXuan L TangJohn R Burnett
Published in: Expert opinion on investigational drugs (2024)
Keyphrases
  • low density lipoprotein
  • crispr cas
  • genome editing
  • genome wide
  • stem cells
  • mesenchymal stem cells